UFP Technologies, Inc. (UFPT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. UFP Technologies, Inc. is a contract development and manufacturing organization specializing in single-use and single-patient medical devices. The company operates as a single reportable segment and continues a strategy of organic growth complemented by strategic acquisitions.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $151.2 million | $110.2 million | $299.3 million | $215.2 million |
| Gross Profit | $43.5 million | $33.0 million | $85.7 million | $63.1 million |
| Gross Margin | 28.8% | 30.0% | 28.6% | 29.3% |
| Operating Income | $24.3 million | $18.0 million | $47.5 million | $33.9 million |
| Net Income | $17.2 million | $13.6 million | $34.4 million | $26.2 million |
| Diluted EPS | $2.21 | $1.75 | $4.42 | $3.38 |
| Cash from Operations (YTD) | $39.1 million (2025) vs $22.4 million (2024) | |||
| Total Debt (Outstanding) | $163.6 million (as of June 30, 2025) | |||
| Cash & Equivalents | $14.9 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 37.2% in Q2 and 39.1% YTD compared to 2024. This growth is primarily driven by acquisitions completed in 2024 (Marble, AJR, Welch, AQF) and 2025 (AJR Specialty/Custom Foam), which contributed approximately $35.7 million in Q2 sales. Organic sales growth was 4.9% in Q2.
- Margin Compression: Gross margin decreased to 28.8% in Q2 from 30.0% in the prior year. Management attributes a $1.2 million increase in cost of sales to inefficiencies during the onboarding of new labor at the newly acquired AJR operations.
- Interest Expense: Net interest expense rose significantly to $2.7 million in Q2 (from $0.6 million in Q2 2024) due to higher debt levels incurred to fund 2024 acquisitions.
- Customer Concentration: Two customers (Intuitive Surgical SARL and Stryker Corporation) accounted for 27.4% and 20.3% of Q2 net sales, respectively.
Guidance, Outlook, and Risks
- Acquisition Strategy: The company continues to pursue growth through acquisitions. Subsequent to the reporting period, UFP acquired Universal Plastics & Engineering Company (UNIPEC) for $7.5 million and Techno Plastics Industries (TPI) for $4.5 million in July 2025.
- Tariff Impact: The company estimates a potential $9 million annual increase in costs due to tariffs passed through by raw material suppliers. Management intends to pass these costs to customers but notes the environment remains dynamic.
- Liquidity: The company maintains a $275 million credit facility (consisting of a $125 million term loan and $150 million revolver) maturing in June 2029. As of June 30, 2025, $163.6 million was outstanding, with a weighted average interest rate of 5.7%.
- Regulatory Changes: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. The company is evaluating the impact but does not expect a material effect on income tax expense.
- Risks: Key risks include customer concentration (reliance on Intuitive Surgical and Stryker), integration challenges of recent acquisitions, potential supply chain disruptions, and the impact of global trade tariffs.
Investor Verification Checklist
- Verify the timeline for resolving inefficiencies at the AJR operations to confirm if gross margins will recover to prior levels.
- Monitor the company's ability to pass through estimated $9 million in tariff-related cost increases to customers without volume erosion.
- Review the integration progress and financial contribution of the 2024 acquisitions (Marble, AJR, Welch, AQF) and the subsequent 2025 acquisitions (UNIPEC, TPI).
- Assess the stability of revenue from the top two customers, which collectively represent over 47% of Q2 sales.
- Track debt service requirements and covenant compliance under the $275 million credit facility, particularly given the increased interest expense.